Evidence map›Paper›PMID 41100734›Full record

ArticleBlood2026

Human missense variants in F3 impair the initiation of blood coagulation.

Shabbir A Ansari, Marisa A Brake, Nishtha Pathak, James T Flaumenhaft, Jacob G Ludington, Natasha Panwar, Ernest Turro, Sol Schulman

Abstract read
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shabbir A AnsariDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.ORCID 0000-0002-1939-7066
Marisa A BrakeDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.ORCID 0000-0002-0385-0428
Nishtha PathakDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
James T FlaumenhaftDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Jacob G LudingtonDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.ORCID 0000-0001-7580-0158
Natasha PanwarDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
Ernest TurroDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-1820-6563
Sol SchulmanDivision of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.ORCID 0000-0002-5229-3592

Funding

PROGRAM IN BLOOD COAGULATION AND VASCULAR BIOLOGYT32HL007917 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Robert C Flaumenhaft · 1999 to 2026
$11.1M
Functional genetics of tissue factor in bleeding and thrombotic riskDP5OD028129 · OD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SCHULMAN, SOL · 2019 to 2023
$2.2M
Genetic architecture of tissue factor expressionR01HL175060 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Sol Schulman · 2024 to 2026
$2.0M
Lipid peroxidation- and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulationK99HL166778 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ANSARI, SHABBIR AHMED · 2023 to 2024
$329k
NHLBI NIH HHS K99 HL166778NHLBI NIH HHS R01 HL175060NHLBI NIH HHS T32 HL007917NIH HHS DP5 OD028129
6 · The paper itself

Abstract

abstractTissue factor (TF), encoded by F3, binds factor VII (FVII)/activated factor VII (FVIIa) to initiate blood coagulation. Because standard clinical assays do not measure endogenous TF directly, the extent to which human F3 variants affect blood coagulation is unknown. We sought to determine the effect of the human TF missense variants with the highest allele frequency as well as additional rare variants occurring at sites predicted to perturb the initiation of blood coagulation. The variants with the highest allele frequency did not affect coagulation activation. By contrast, some rare human TF missense substitutions did profoundly affect TF-initiated plasma clotting time and the activation of FIX and FX by 2 distinct mechanisms: by precluding TF interaction with FVIIa, or by altering the TF exosite to prevent macromolecular but not amidolytic substrate cleavage. Individuals heterozygous for the rare p.Gly196Arg variant have reduced basal FVIIa-antithrombin complex and D-dimer levels but no major differences in TF or FVII levels. Gly196Arg supported impaired FVII autoactivation in vitro. These data demonstrate that rare missense variants in F3 can impair the activation of FVII, FIX, and FX, and suggest these variants impair the basal activation of blood coagulation in humans.

Indexed as

Blood CoagulationMutation, MissenseThromboplastinGene FrequencyHumansThromboplastin

Identifiers

PMID41100734
PMCPMC12773718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.